2023
Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions
van der Horst M, Meijer Y, de Boer N, Guloksuz S, Hasan A, Siskind D, Wagner E, consortium C, Müderrisoğlu A, Privat A, Bouhuis A, Hasan A, Jongkind A, Gonzalez-Pinto A, Santacana A, D'Agostino A, Ertugrul A, Yağcioğlu A, Crespo-Facorro B, Sanchez-Barbero B, Spuch C, Morgenroth C, de Pinedo C, Casetta C, Bousman C, Pantelis C, Ovejas-Catalán C, Garcia-Rizo C, Okhuijsen-Pfeifer C, Cohen D, Ristic D, Beld E, Repo-Tiihonen E, Wagner E, Jeger-Land E, Vilella E, Bekema E, Sepúlveda S, Seghi F, Wiedenmann F, Martini F, Serio F, Vairano F, Mercuriali G, Boido G, Yoca G, van Beek H, Gijsman H, Tuppurainen H, Everall I, Novakovic I, Zorrilla I, Erdoğan I, Sapienza J, Bogers J, Tiihonen J, Vázquez-Bourgon J, van Os J, Schneider-Thoma J, Luykx J, Grootens K, Mar-Barrutia L, Martorell L, Bak M, Spangaro M, de Vos M, de Koning M, Garriga M, Lähteenvuo M, Bosia M, van der Horst M, Babaoğlu M, Veereschild M, Manchia M, Edlinger M, Fuentes-Pérez P, Paribello P, Lopez-Pena P, Kahn R, Cavallaro R, Veerman S, Gutwinski S, Schreiter S, Ripke S, Baltanás T, Oviedo-Salcedo T, Hallikainen T, Görlitz T, Alink W, Ayhan Y, Okhuijsen-Pfeifer C, Luykx J. Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions. Psychiatry Research 2023, 330: 115539. PMID: 37988817, DOI: 10.1016/j.psychres.2023.115539.Peer-Reviewed Original ResearchConceptsAdverse drug reactionsClinical factorsDrug reactionsPrevalence ratesCommon adverse drug reactionsWeight gainSignificant weight gainMulti-center studyImproved treatment outcomesClozapine blood levelsClozapine monotherapyClozapine treatmentLower BMIBlood levelsTreatment outcomesHigh prevalencePrevalenceMean numberYounger participantsSex differencesParticipantsTreatmentComprehensive dissectionConstipationHypersalivation
2013
Depressive Symptoms in Crohn's Disease: Relationship with Immune Activation and Tryptophan Availability
Guloksuz S, Wichers M, Kenis G, Russel M, Wauters A, Verkerk R, Arts B, van Os J. Depressive Symptoms in Crohn's Disease: Relationship with Immune Activation and Tryptophan Availability. PLOS ONE 2013, 8: e60435. PMID: 23544139, PMCID: PMC3609785, DOI: 10.1371/journal.pone.0060435.Peer-Reviewed Original ResearchConceptsCrohn's diseaseDisease activityImmune activationDepressive symptomsDepression scoresTrp availabilityΑ treatmentTryptophan availabilityNegative APPsAnti-tumor necrosis factorPast depressive disorderTNF-α treatmentSymptoms of depressionQuality of lifeCD patientsIBDQ scoreImmune markersComorbid depressionDepressive disorderNecrosis factorInflammatory reactionPatientsSymptomsDiseaseTreatment
2012
Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?
Jauhar S, Guloksuz S, Andlauer O, Lydall G, Marques J, Mendonca L, Dumitrescu I, Roventa C, De Vriendt N, Van Zanten J, Riese F, Nwachukwu I, Nawka A, Psaras R, Masson N, Krishnadas R, Volpe U, European Federation of Psychiatric Trainees' Research Group. Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence? BMC Psychiatry 2012, 12: 27. PMID: 22463055, PMCID: PMC3337226, DOI: 10.1186/1471-244x-12-27.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsCognitive behavioral therapyUse of SGAsSecond-generation antipsychotic medicationsKnowledge of trialQuestionnaire-based studyAntipsychotic medicationAntipsychotic treatmentTreatment choicePatientsBehavioral therapyForms of psychotherapyOwn treatmentAntipsychoticsTreatmentPsychosisTrialsPsychiatry traineesEfficacyTrainees
2010
PW01-264 - How would European trainees treat bipolar disorder for their patients and themselves, and what influences decision-making?
Jauhar S, Lydall G, Riese F, Marques J, Bendix M, Andlauer O, Gerber S, De Vriendt N, Dumitrescu I, Nawka A, Guloksuz S, Mendonca L, Nwachukw I, Psaras R, Roventa C, Giacco D, Mufic A, Dobrzynska E, Nazaraliev A, Van Zanten J, Group E. PW01-264 - How would European trainees treat bipolar disorder for their patients and themselves, and what influences decision-making? European Psychiatry 2010, 25: 1596-1597. DOI: 10.1016/s0924-9338(10)71577-7.Peer-Reviewed Original Research